Hims & Hers' February gains were important in bringing it over the SPAC $10 level, says Jim Cramer
'Mad Money' host Jim Cramer takes a look at Hims & Hers to assess if its a good healthcare move for your portfolio.
Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Hims & Hers Stock Drops 12.8% After Short Report
A short report was published that makes a case against Hims & Hers' new GLP-1 product. The report was put out by a media organization with ties to a fund that is also a short-seller of the stock.
3 Reasons to Buy Hims & Hers Health Stock Now
Summer has officially begun, but some stocks are receiving a chilly reception today.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health Stock Soared This Week: Here's Why
Hims & Hers recently launched weight loss drugs at a disruptive price point. The company is growing revenue quickly.
The Ultimate Growth Stock to Buy With $20 Right Now
Hims & Hers has entered the popular GLP-1 agonist category. Weight loss has quickly become a significant, potentially unexpected catalyst.
Hims & Hers Is Changing the Game
GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption.
Hims & Hers rolls out weight-loss shots much cheaper than Ozempic, Wegovy
Health and wellness company Hims & Hers announced Monday that it is introducing injectable weight-loss drugs at a fraction of the cost of Ozempic and Wegovy.
Weight loss drug roll-out sends Hims & Hers stock soaring
Weight loss drugs helped Hims & Hers Health (NYSE:HIMS) put value on, with the stock soaring some 30% higher in ‘afterhours' trade on Monday. The online consumer healthcare brand last night announc...
Celebrity Fitness Trainer Jillian Michaels weighs in on Hims & Hers offering weight-loss drugs
Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m.
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
Shares of Hims & Hers Health (NYSE: HIMS ) stock are skyrocketing higher by over 25% after the telehealth company announced that it would provide access to GLP-1 weight-loss injections. Hims & Hers...
Stock Market Mayhem: 3 Companies Ready to Shake Things Up
With the stock market heating up again, consider investing in disruptive stocks to buy. Betting on disruptive stocks, especially at the right prices, can prove incredibly rewarding.
Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Anja Manuel to the company's Board...
Earnings Estimates Rising for Hims & Hers Health (HIMS): Will It Gain?
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Related Companies